ApoB100/LDLR-/- Hypercholesterolaemic mice as a model for mild cognitive impairment and neuronal damage

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Ramírez, Carlos ^a   Sierra, Saleta ^a   Tercero, Inmaculada ^a   Vázquez, Jose Antonio ^a   Pineda, Antonia ^a   Manrique, Tatiana ^a   Burgos, Javier S ^a  

^a BioPharma Division   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

AGE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ASTROCYTOSIS; BASAL AMYGDALA; BRAIN REGION; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; COGNITION; CONTROLLED STUDY; ENTORHINAL CORTEX; EPISODIC MEMORY; FAMILIAL HYPERCHOLESTEROLEMIA; GRIP STRENGTH; HIPPOCAMPUS; LIPID PEROXIDATION; LOCOMOTION; MALE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MOUSE; NEURONAL DAMAGE; NEUROPATHOLOGY; NONHUMAN; OPEN FIELD TEST; ROTAROD TEST; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; AORTA DISEASE; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; ENZYME IMMUNOASSAY; HOMOZYGOTE; HYPERCHOLESTEROLEMIA; MOUSE MUTANT; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

ANIMALIA; MURINAE; MUS; MUS MUSCULUS;

AMYLOIDOSIS; ANIMALS; AORTIC DISEASES; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; BEHAVIOR, ANIMAL; CELLS, CULTURED; CHOLESTEROL; DISEASE MODELS, ANIMAL; HOMOZYGOTE; HYPERCHOLESTEROLEMIA; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MILD COGNITIVE IMPAIRMENT; NEURONS; RECEPTORS, LDL;

EID: 79960795564     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022712     Document Type: Article

References (53)

1. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K, (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64: 277-281.
2. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, et al. (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61: 199-205.
3. Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, et al. (2005) High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64: 1689-1695.
4. Zambon D, Quintana M, Mata P, Alonso R, Benavent J, et al. (2010) Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med 123: 267-274.
5. Civeira F, (2004) Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173: 55-68.
6. Harris-White ME, Frautschy SA, (2005) Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition. Curr Drug Targets CNS Neurol Disord 4: 469-480.
7. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, et al. (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126: 88-94.
8. Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ, (2006) Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem 99: 438-449.
9. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, et al. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-331.
10. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC, (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13: 455-459.
11. Mulder M, Jansen PJ, Janssen BJ, van de Berg WD, van der Boom H, et al. (2004) Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol Dis 16: 212-219.
12. Cao D, Fukuchi K, Wan H, Kim H, Li L, (2006) Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging 27: 1632-1643.
13. Powell-Braxton L, Veniant M, Latvala RD, Hirano KI, Won WB, et al. (1998) A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med 4: 934-938.
14. Mizoguchi T, Edano T, Koshi T, (2004) A method of direct measurement for the enzymatic determination of cholesteryl esters. J Lipid Res 45: 396-401.
15. Zadrozniak A, Wojda E, Wlaz A, Luszczki JJ, (2009) Characterization of acute adverse-effect profiles of selected antiepileptic drugs in the grip-strength test in mice. Pharmacol Rep 61: 737-742.
16. Bouet V, Freret T, Toutain J, Divoux D, Boulouard M, et al. (2007) Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse. Exp Neurol 203: 555-567.
17. Lalonde R, Strazielle C, (2008) Relations between open-field, elevated plus-maze, and emergence tests as displayed by C57/BL6J and BALB/c mice. J Neurosci Methods 171: 48-52.
18. Dere E, Huston JP, De Souza Silva MA, (2005) Integrated memory for objects, places, and temporal order: evidence for episodic-like memory in mice. Neurobiol Learn Mem 84: 214-221.
19. Ramirez C, Tercero I, Pineda A, Burgos JS, (2011) Simvastatin is the Statin that Most Efficiently Protects Against Kainate-Induced Excitotoxicity and Memory Impairment. J Alzheimers Dis 24: 161-174.
20. Gottlieb M, Leal-Campanario R, Campos-Esparza MR, Sanchez-Gomez MV, Alberdi E, et al. (2006) Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. Neurobiol Dis 23: 374-386.
21. Toyokuni S, Miyake N, Hiai H, Hagiwara M, Kawakishi S, et al. (1995) The monoclonal antibody specific for the 4-hydroxy-2-nonenal histidine adduct. FEBS Lett 359: 189-191.
22. Walz W, Lang MK, (1998) Immunocytochemical evidence for a distinct GFAP-negative subpopulation of astrocytes in the adult rat hippocampus. Neurosci Lett 257: 127-130.
23. Prasanthi JR, Huls A, Thomasson S, Thompson A, Schommer E, et al. (2009) Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol Neurodegener 4: 1.
24. Shobab LA, Hsiung GY, Feldman HH, (2005) Cholesterol in Alzheimer's disease. Lancet Neurol 4: 841-852.
25. Nimpf J, Schneider WJ, (2000) From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2. Biochim Biophys Acta 1529: 287-298.
26. Gopalraj RK, Zhu H, Kelly JF, Mendiondo M, Pulliam JF, et al. (2005) Genetic association of low density lipoprotein receptor and Alzheimer's disease. Neurobiol Aging 26: 1-7.
27. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, et al. (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893.
28. Bereczki E, Bernat G, Csont T, Ferdinandy P, Scheich H, et al. (2008) Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. J Proteome Res 7: 2246-2252.
29. Cole GM, Beech W, Frautschy SA, Sigel J, Glasgow C, et al. (1999) Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro. J Neurosci Res 57: 504-520.
30. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, et al. (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 24: 114-127.
31. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, et al. (1998) Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252: 711-715.
32. Caramelli P, Nitrini R, Maranhao R, Lourenco AC, Damasceno MC, et al. (1999) Increased apolipoprotein B serum concentration in Alzheimer's disease. Acta Neurol Scand 100: 61-63.
33. Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, et al. (2008) High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem 106: 475-485.
34. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, et al. (2010) Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol 67: 1491-1497.
35. Sabbagh M, Zahiri HR, Ceimo J, Cooper K, Gaul W, et al. (2004) Is there a characteristic lipid profile in Alzheimer's disease? J Alzheimers Dis 6: 585-589 discussion 673-581.
36. Cankurtaran M, Yavuz BB, Halil M, Dagli N, Cankurtaran ES, et al. (2005) Are serum lipid and lipoprotein levels related to dementia? Arch Gerontol Geriatr 41: 31-39.
37. Suryadevara V, Storey SG, Aronow WS, Ahn C, (2003) Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J Gerontol A Biol Sci Med Sci 58: M859-861.
38. Buchman AS, Wilson RS, Boyle PA, Bienias JL, Bennett DA, (2007) Grip strength and the risk of incident Alzheimer's disease. Neuroepidemiology 29: 66-73.
39. Leduc V, Jasmin-Belanger S, Poirier J, (2010) APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med 16: 469-477.
40. Stewart R, Richards M, Brayne C, Mann A, (2001) Vascular risk and cognitive impairment in an older, British, African-Caribbean population. J Am Geriatr Soc 49: 263-269.
41. Li L, Cao D, Garber DW, Kim H, Fukuchi K, (2003) Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol 163: 2155-2164.
42. Greenwood CE, Winocur G, (1996) Cognitive impairment in rats fed high-fat diets: a specific effect of saturated fatty-acid intake. Behav Neurosci 110: 451-459.
43. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, et al. (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151-154.
44. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, et al. (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 46: 1592-1596.
45. Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr, Gandy S, et al. (2010) Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 77: 82-102.
46. Bodovitz S, Klein WL, (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271: 4436-4440.
47. Kawai M, Kalaria RN, Harik SI, Perry G, (1990) The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol 137: 1435-1446.
48. Jellinger KA, (2007) The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 113: 349-388.
49. Breslow JL, (1996) Mouse models of atherosclerosis. Science 272: 685-688.
50. Selkoe DJ, Bell DS, Podlisny MB, Price DL, Cork LC, (1987) Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 235: 873-877.
51. Duyckaerts C, Potier MC, Delatour B, (2008) Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 115: 5-38.
52. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F, (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20.
53. Poirier J, (2003) Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 9: 94-101.